Pulmonary Tuberculosis Nursing Care Plans

Your job with a TB patient breaks down to three things: keep them on their drugs, keep them from infecting anyone else, and keep their airway and nutrition stable while the regimen does its work. Everything below serves those goals.

What is Pulmonary Tuberculosis?

Pulmonary tuberculosis (PTB) is an acute or chronic infection caused by Mycobacterium tuberculosis. It produces pulmonary infiltrates, granulomas with caseation, fibrosis, and cavitation. The lungs are the most common site, and 85% of diagnosed patients present with pulmonary symptoms.

TB is climbing again in the United States. In 2024 the country reported 10,388 cases at an incidence of 3.1 per 100,000, up from 9,633 cases in 2023 and 8,300 in 2022. That is the fourth straight annual increase and the highest case count since 2011, reflecting a return past pre-pandemic levels after the 2020 dip tied to missed and delayed diagnoses.

Humans are the only known reservoir. The organism spreads as an airborne aerosol from someone in the infectious stage. The highest-risk patients are those living in crowded, poorly ventilated conditions, the immunocompromised, the homeless, people who use drugs, and immigrants from or visitors to endemic countries. Anyone debilitated by AIDS, cancer, advanced age, or malnutrition is also vulnerable, because a weakened immune system lets dormant organisms reactivate and multiply.

Active PTB shows up as cough, weight loss or anorexia, fever, night sweats, hemoptysis, chest pain, and fatigue. Expect abnormal breath sounds over the upper lobes, with rales or bronchial breath sounds signaling consolidation.

When latent infection flares into active disease, it is called reactivation TB, and it is often drug resistant. Multidrug-resistant TB (MDR-TB) is rising, especially in large cities, in patients previously treated with antitubercular drugs, and in those who did not complete a regimen. Untreated, it can move from diagnosis to death in as little as 4 to 6 weeks. Primary MDR-TB comes from person-to-person transmission of a resistant organism. Secondary MDR-TB usually comes from nonadherence or inappropriate treatment.

Nursing Problem Priorities

1. Adherence to the medication regimen.
2. Reduced transmission of M. tuberculosis.
3. Disease information and patient education.
4. Emotional support and psychosocial needs.
5. A multidisciplinary plan, including followup appointments and directly observed therapy when indicated.

Nursing Assessment

Assess for these subjective and objective findings:

• Persistent cough lasting weeks to months
• Fatigue, weakness, decreased energy
• Night sweats and unexplained weight loss
• Loss of appetite and decreased intake
• Chest pain or discomfort
• Shortness of breath or difficulty breathing
• Crackles, wheezes, or decreased breath sounds
• Positive tuberculin skin test (Mantoux) or interferon-gamma release assay (IGRA)
• Infiltrates, nodules, or cavities on chest X-ray
• Sputum smear or culture positive for M. tuberculosis
• Elevated ESR or CRP
• Decreased oxygen saturation
• Signs of malnutrition

Contributing factors to assess for:

• Decreased ciliary action and stasis of secretions
• Tissue destruction and extension of infection
• Lowered resistance and suppressed inflammatory process
• Malnutrition
• Environmental exposure
• Thick, viscous, or bloody secretions
• Poor cough effort and fatigue
• Tracheal or pharyngeal edema
• Reduced effective lung surface and atelectasis
• Destruction of the alveolar-capillary membrane
• Insufficient knowledge to avoid exposure
• Insufficient financial resources

Nursing Goals

• The patient identifies interventions to prevent or reduce spread of infection.
• The patient demonstrates techniques and lifestyle changes that promote a safe environment.
• The patient maintains a patent airway.
• The patient expectorates secretions without assistance.
• The patient verbalizes understanding of the regimen and the rationale behind it.

1. Infection Control and Management

Most active TB develops after a long latency, often years after the initial infection. This is secondary, or reactivation, TB, and the lesions sit in the lung apices. A smaller group develops secondary TB after a second exposure.

Review the pathology and how TB spreads. Walk the patient through active versus inactive phases and transmission by airborne droplets during coughing, sneezing, talking, and singing. Patients who understand transmission take steps to protect their family and accept why they have to finish the regimen.

Identify others at risk. Household members, close contacts, and coworkers may need preventive drug therapy. High-burden groups include recent arrivals from endemic areas, healthcare workers, and HIV-positive patients.

Monitor temperature. Fever signals ongoing infection and is present in 60 to 85% of PTB patients. It is one of the more reliable markers of TB activity.

Identify reactivation risk factors. Alcoholism, malnutrition, intestinal bypass surgery, immunosuppressive drugs, corticosteroids, diabetes, cancer, and the postpartum period all lower resistance. Latent TB reactivates readily after immunosuppression. Primary progressive TB shows up most in children, malnourished patients, the immunosuppressed, and long-term steroid users.

Monitor liver function (AST/ALT). This catches drug-induced hepatitis. Liver studies are required for every patient on isoniazid. Patients on ethambutol also need monitoring for retinopathy.

Teach cough and disposal technique. Have the patient cough or sneeze into tissue, never spit, dispose of tissue properly, and wash hands. Get a return demonstration. Poor technique and low awareness drive both transmission and nonadherence.

Bring the family into home infection control. By the time TB is diagnosed, the household has usually already been exposed. Instruct the patient to cover the mouth and nose when coughing or sneezing, sleep alone, and avoid visitors until they are noninfectious.

Use respiratory isolation when indicated. Place patients with suspected or confirmed infectious TB in an airborne infection isolation room, away from others. Standard masks do not stop acid-fast bacilli, so particulate respirators are required. Frame isolation as protecting others, and acknowledge the stigma the patient feels.

Stress uninterrupted drug therapy. The contagious period may last only 2 to 3 days after chemotherapy starts, but with cavitation or moderately advanced disease the risk of spread can continue up to 3 months. Multidrug regimens over long periods are hard to sustain, so use directly observed therapy (DOT). Most patients do well because treatment works. Untreated, TB mortality is over 50%.

Reinforce followup and serial sputum cultures. MDR-TB needs at least 18 to 24 months of therapy with at least 3 drugs known to be effective against the organism and not previously used. Extend to 24 months for severe symptoms or HIV coinfection.

Support balanced intake. Offer small, frequent snacks instead of large meals. Anorexia and preexisting malnutrition lower resistance and slow healing.

Notify the local health department. This is required by law and drives contact tracing. Treatment runs long and is usually managed in the community with public health nurse monitoring. State health departments report cases to the CDC.

Administer anti-infectives as ordered. Initial therapy for uncomplicated disease usually runs 4 drugs. Current LTBI guidance favors short rifamycin-based regimens, with daily isoniazid as an alternative.

Give first-line drugs. Isoniazid (INH), rifampin (Rifadin), ethambutol (Myambutol), pyrazinamide (PZA), streptomycin, and rifapentine (Priftin). INH is the drug of choice for infected patients and those at risk. A short course of INH, rifampin for 6 months, PZA, and ethambutol or streptomycin runs at least 2 months (until sensitivities are known or sputum clears), followed by 3 more months of INH. Add ethambutol if CNS or disseminated disease is present or INH resistance is suspected.

Give second-line drugs when needed. Ethionamide (Trecator-SC), para-aminosalicylate (PAS), cycloserine (Seromycin), and capreomycin (Capastat). Extend therapy up to 24 months for reactivation, extrapulmonary reactivation, or comorbidities like diabetes or silicosis. Consider 12 months of INH prophylaxis in HIV-positive patients with positive PPD.

Give bedaquiline (Sirturo) as ordered. The FDA approved bedaquiline for MDR-TB on December 28, 2012, the first new anti-TB drug in 40 years. Cost still limits access for many of the patients who need it most.

Educate families about BCG vaccination for children. BCG's protective effect is debated, but childhood vaccination remains a key tool against TB in high-burden countries.

Hold the team to respiratory protection. Staff handling these patients use particulate respirators and follow a respiratory protection program with proper training.

2. Airway Clearance

TB inflammation produces cough with sputum or blood, dyspnea, chest pain, night sweats, and poor appetite. Sputum accumulates and obstructs the airway, so ineffective airway clearance is one of the most common problems you will manage.

Assess respiratory function. Note breath sounds, rate, rhythm, depth, and accessory muscle use. Diminished sounds suggest atelectasis. Rhonchi and wheezes mean retained secretions and increased work of breathing.

Evaluate the cough and sputum. Document the character and amount of sputum and any hemoptysis. Thick secretions from infection or poor hydration are hard to clear. Bloody sputum comes from cavitation or bronchial ulceration and may need further workup.

Auscultate the lung fields. Decreased airflow marks areas filled with fluid or secretions. Crackles, rhonchi, and wheezes on inspiration and expiration reflect fluid, thick secretions, and obstruction.

Position for expansion. Place the patient in semi- or high-Fowler's and assist with coughing and deep breathing. This opens atelectatic areas and moves secretions toward larger airways.

Clear and suction as needed. Suction the mouth and trachea when the patient cannot expectorate, which prevents obstruction and aspiration. Wear a particulate respirator for endotracheal suctioning on suspected or confirmed TB.

Maintain fluid intake of at least 2500 mL/day unless contraindicated. Fluids thin secretions, replace insensible losses from fever and tachypnea, and correct dehydration.

Give humidified air and oxygen. This keeps mucous membranes from drying and thins secretions.

Be ready for emergency intubation. Rare cases of bronchogenic TB with laryngeal edema or acute pulmonary bleeding need it. The most common reason for TB-related ICU admission is acute respiratory failure from pneumonia or ARDS, and moderate to severe ARDS needs mechanical ventilation without delay.

Prepare for chest physiotherapy. Percussion, vibration, drainage, deep breathing, and cough exercises help mobilize sputum.

3. Gas Exchange

TB scars lung tissue and drops compliance, so patients develop impaired gas exchange, progressive dyspnea, and deconditioning.

Assess for dyspnea on a 0 to 10 scale, along with tachypnea, diminished breath sounds, increased respiratory effort, limited chest expansion, and fatigue. PTB ranges from a small patch of bronchopneumonia to diffuse inflammation, caseous necrosis, pleural effusion, and extensive fibrosis. A scale clarifies the degree of difficulty and tracks change.

Watch mentation and skin color. Note cyanosis or changes in mucous membranes and nail beds. Retained secretions and airway compromise impair oxygenation. Diaphoresis, pallor, and cool clammy skin are late signs of severe hypoxemia. Subtle mental status changes can progress to coma over days to weeks, especially with tuberculous meningitis.

Auscultate breath sounds. Expect abnormal sounds over the upper lobes, with rales or bronchial sounds signaling consolidation.

Monitor heart rate and rhythm. Tachycardia appears early as the sympathetic nervous system releases catecholamines to push oxygen to the tissues.

Teach pursed-lip breathing on exhalation, especially with fibrosis or parenchymal destruction. It holds the airways open longer, moves more air, and eases dyspnea so the patient can stay more active.

Promote rest and limit activity. Reducing oxygen demand during respiratory compromise eases symptoms. Lung volume loss and impaired gas exchange cause exercise-induced desaturation and breathlessness that limit daily function.

Use the 6-minute walk test when indicated. It is a simple functional measure for tracking status, treatment response, and prognosis.

Monitor serial ABGs and pulse oximetry. A falling PaO2 or saturation, or a rising PaCO2, means it is time to intervene or change the plan. ABGs vary with the location and severity of lung damage.

Give supplemental oxygen as appropriate. It corrects hypoxemia from reduced ventilation and diminished alveolar surface. TB sequelae limit oxygen transport and lower SpO2.

Give corticosteroids as prescribed. They are adjuvants, mainly for extrapulmonary disease, severe PTB, or ARDS, working by suppressing the lymphokines and cytokines behind constitutional symptoms and tissue damage.

Refer to pulmonary rehabilitation as indicated. Rehab helps patients with prior TB and impaired lung function, consistent with ATS/ERS guidance for chronic respiratory disease.

4. Nutritional Balance

Malnutrition runs about 70% in TB patients, and in this group it carries a 2-fold higher risk of dying from the disease. WHO entitles every active TB patient to individualized nutritional assessment and management, including counseling and therapy.

Document nutritional status on admission. Note skin turgor, current weight and degree of loss, oral mucosa, ability to swallow, bowel sounds, and any nausea, vomiting, or diarrhea. A BMI below 18.5 kg/m² flags chronic malnutrition with loss of both fat and muscle.

Ask about the usual diet and include patient preferences. Many TB patients simply do not eat enough each day, and matching their preferences improves intake.

Monitor I&O and weight. Weigh to the nearest 0.1 kg on a digital standing scale, shoes off, to track the effectiveness of nutritional support.

Investigate anorexia, nausea, and vomiting and link them to medications when possible. Track stool frequency, volume, and consistency. Patients coinfected with HIV often have GI symptoms, poor appetite, and accelerated wasting.

Monitor BUN, serum protein, prealbumin, and albumin. Low values reflect malnutrition, a reversible risk factor for treatment failure. Malabsorption worsens with comorbid diabetes or HIV/AIDS.

Provide frequent rest periods. Fever raises metabolic demand. Conserving energy shortens recovery and protects muscle function.

Give oral care before and after respiratory treatments. Clearing the bad taste from sputum and medications reduces nausea. Use a soft-bristled toothbrush and provide oral care 3 times daily, especially after expectoration.

Encourage small, frequent, high-protein, high-carbohydrate meals. This maximizes intake without the fatigue and gastric irritation of large meals. Use medical nutrition supplements when regular food is not enough.

Let the family bring food and share meals unless contraindicated. A normal social mealtime and familiar foods improve intake in patients who start out with poor appetite.

Push protein and vitamin-rich foods. Protein from milk, eggs, meat, and fish, or from cereals and pulses. Leafy vegetables and fruit supply vitamins and minerals. Raise energy and protein without raising volume.

Refer to a dietitian. A dietitian builds a plan around metabolic needs, preferences, and finances, and reassesses through treatment and rehabilitation.

Schedule respiratory treatments 1 to 2 hours before or after meals. This cuts nausea and vomiting tied to medications and treatments on a full stomach.

Give antipyretics as appropriate. Fever raises calorie consumption. Acetaminophen is the common choice.

Connect patients to nutrition programs. Food assistance, integrated TB program support, and education on undernutrition all strengthen recovery.

5. Pharmacologic Management

The goal is to clear the organism, treat the infection, and prevent resistance, which takes a combination of drugs.

First-line drugs:

• Isoniazid (INH): A bactericide effective against intracellular and extracellular organisms; it blocks mycolic acid synthesis in the cell wall. Watch for peripheral neuropathy and hepatitis.
• Rifampin (Rifadin): Inhibits bacterial RNA polymerase. Expect harmless reddish-orange discoloration of urine, sweat, tears, and other fluids.
• Pyrazinamide (PZA): Disrupts the bacteria's energy metabolism and hits dormant, non-replicating organisms, shortening therapy. Monitor liver function for toxicity.
• Ethambutol (Myambutol): Combined with other drugs to prevent resistance. Can cause optic nerve damage and visual impairment.
• Rifabutin (RBT): Substitutes for rifampin when drug interactions or resistance rule rifampin out.
• Rifapentine (Priftin): Long half-life supports once-weekly regimens for drug-susceptible PTB and better adherence.
• Streptomycin: An aminoglycoside from Streptomyces griseus used for TB and sensitive gram-negative infections.

Second-line drugs: ethionamide (Trecator-SC), para-aminosalicylate (PAS), cycloserine (Seromycin), capreomycin (Capastat), and bedaquiline (Sirturo). Reserved for drug-resistant TB or when first-line drugs fail or are not tolerated.

Mucolytics: acetylcysteine (Mucomyst) thins secretions for easier clearance.

Bronchodilators: oxtriphylline (Choledyl) and theophylline (Theo-Dur) widen the airway and improve oxygen delivery when airflow is reduced.

Corticosteroids (prednisone): Useful with extensive involvement and profound hypoxemia, or when inflammation is life-threatening, including tuberculous meningitis, where they reduce inflammation and intracranial pressure.

6. Patient Education

Education here has one purpose: get the patient to finish the full course, manage side effects, and stop spreading infection.

Assess readiness to learn. Gauge fear, fatigue, participation, the best environment, how much to cover at once, and language and literacy. Self-efficacy drives self-motivation, and learning happens at an individual pace.

Teach which symptoms to report: hemoptysis, chest pain, fever, difficulty breathing, hearing loss, and vertigo. These can signal progression, reactivation, or drug side effects. TB can also affect the pericardium and the eye.

Evaluate job- and environment-related risk. Crowded or closed settings raise risk to others. High-risk groups include hospital staff, inner-city and nursing-home residents, and prisoners.

Assess cultural and personal health beliefs. Beliefs about how TB spreads and how it should be treated shape adherence and may differ from the medical model.

Provide written medication and followup schedules. Written material relieves the memory burden and repetition reinforces learning. Have the patient teach back to confirm understanding.

Use plain language at the right level. Skip jargon, match the patient's reading level, and for patients who do not read or write, give verbal instructions with visual cues, such as a picture of each drug with the dose time in large numbers.

Do not overload. Cover the most essential topics first, in case the patient does not return. People retain the beginning and end of a session better than the middle.

Use professional interpreters for patients with limited English. Do not rely on family members as interpreters, though you can include them if the patient wants.

Incorporate the patient's beliefs into the plan where you can, while clearly explaining why the full medication course matters. Traditional remedies may complement treatment only under provider oversight.

Let the patient and family voice fears and concerns. Answer factually and watch for prolonged denial, which undermines adherence. Rapport and trust are critical, and your nonverbal cues carry judgment whether you intend it or not.

Recruit family support. Family and peers help patients keep DOT appointments and stay on medication. Some health departments use former TB patients as peer workers.

Reinforce a high-protein, high-carbohydrate diet and adequate fluids. Meeting metabolic needs minimizes fatigue, and fluids help expectoration. Patients on food supplements during treatment tend to gain more weight.

Introduce directly observed therapy (DOT). A healthcare worker watches the patient swallow every dose. DOT is the worldwide standard and reduces resistance, treatment failure, and relapse.

Explain dosing, frequency, expected effects, and why treatment runs long. Review drug and substance interactions. Patients adhere better when they help choose solutions rather than being told what to do.

Review side effects and solutions: dry mouth, constipation, visual disturbances, headache, orthostatic changes. Anticipating them improves cooperation.

Stress no alcohol while on INH. The combination raises the risk of hepatitis. Monitor hepatic and renal function in patients with abnormal baselines or added hepatotoxicity risk.

Schedule eye exams on ethambutol. Check vision after starting and then monthly. The first sign of toxicity is often reduced ability to perceive green. Optic neuritis is usually reversible if the drug is stopped. Monthly exams are recommended during daily dosing at 25 mg/kg.

Encourage quitting smoking. Smoking raises the risk of contracting TB, raises recurrence risk, and impairs treatment response. Secondhand smoke raises risk too, especially in children.

Review transmission and reactivation hazards. TB spreads mainly by inhaling airborne organisms. Reactivation complications include cavitation, abscess, destructive emphysema, spontaneous pneumothorax, interstitial fibrosis, effusion, empyema, bronchiectasis, hemoptysis, and miliary spread to bone marrow, liver, spleen, kidneys, bones, and brain.

Create an adherence agreement when useful. A written agreement spells out what the patient will do in exchange for specific services or incentives. Review it periodically and adjust as needed.